Archives
VANCOUVER, CANADA / December 2, 2016 – Biolux Research is pleased to announce the expansion of our North American sales force as part of the next phase of OrthoPulse® sales and commercialization. Three new territory managers have joined the Biolux team starting Dec. 1, 2016.
With greater sales presence in North America, combined with in-house marketing and customer support staff, Biolux will be better able to support existing OrthoPulse® doctors as well as improve awareness and education of OrthoPulse® with doctors and patients throughout the United States and Canada.
OrthoPulse® is a clinically proven medical device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement, thus reducing treatment time. OrthoPulse® received FDA clearance in July of 2015 and is cleared by the FDA for use with both braces and clear aligners. The device is designed to be used by patients at home on a daily basis for a total of 10 minutes.
“We are excited to have such a strong and experienced team joining us for our next phase in making Biolux Research the leader in accelerated orthodontics in North America” states Marcel Pordes, Vice President of Business Development for Biolux. “Long orthodontic treatment timelines are still one of the top concerns for orthodontic patients, and we believe that the OrthoPulse® can dramatically change the orthodontic market for doctors by reducing treatment timelines with confidence.”
About Biolux Research
Biolux Research is a world leader in the development of innovative Light Accelerated OrthodonticsTM technology and products for use in orthodontics, implantology, and other dentistry markets. Biolux Research focuses on product development and clinical research, and its proprietary, patented technologies have been developed to enhance clinical outcomes and dramatically reduce treatment timelines in orthodontics and dentistry in a safe, effective and non-invasive approach. www.orthopulse.com or www.bioluxresearch.com
For More Information:
Kevin Strange, President and CEO
Biolux Research
k.strange@bioluxresearch.com